EMA signs deal to receive reports on misuse of psychoactive substances
This article was originally published in SRA
The European Medicines Agency will receive reports from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) on the misuse of medicinal products as part of a new agreement signed between the two organisations1,2.
You may also be interested in...
The UK’s deployment of COVID-19 vaccines has left vaccine manufacturers worried about emerging discussions on dosing strategies that may not be supported by authorized labeling or published clinical data.
Existing importers and manufacturers of certain medical devices can continue marketing their products for six months or until the Indian medtech regulator makes a final decision on their pending licensing applications.
Differences between how Australia and the EU define “central circulatory system” has resulted in different risk classification levels being assigned to some devices in the two jurisdictions.